Pediatric Oncologist Filemon Dela Cruz, MD
PROXC is a multi-institutional effort which aims to facilitate the conduct of basic and translational research and provide clinical and therapeutic insight for pediatric cancers using patient-derived xenografts (PDXs) as validation tools. By federating PDX models developed at collaborating PROXC institutions, multi-directional sharing of models and associated clinical and molecular characterization data, and adoption of harmonized approaches for drug evaluation, PROXC seeks to develop and validate PDX models to accelerate the process of drug prioritization and enable substantive progress in the treatment of pediatric cancer.
Our federated PROXC PDX model portfolio includes:
- >500 PDX Models
- >300 Ped Sarcoma PDXs
- >140 Osteosarcoma
- >40 Ewing Sarcoma
- >70 Rhabdomyosarcoma
- >50 Neuroblastoma
- >20 Wilms Tumor
- >13 Tumor Types
- ~50 Tumor Histologies
What is a patient-derived xenograft (PDX) model?
Patient-derived xenografts (PDX) are cancer models where human tumor tissue or cells are implanted into an immunocompromised mouse which creates an environment allowing natural cancer progression.